Dyadic is a global biotechnology company focused on applying its proprietary gene expression platform to accelerate development, lower production costs and improve performance of biologic vaccines, drugs and other biologic products. The biopharmaceutical gene expression platform is based on the C1 strain of the fungus Myceliophthora thermophila. The microorganism enables the development and large-scale manufacture of low-cost proteins, with the potential to be further developed into a safe and efficient expression system with applications in the production of biologic vaccines and drugs at flexible commercial scales. Dyadic uses their C1 technology for development of human and animal vaccines and drugs such as virus like particles (VLPs), antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters and other therapeutic proteins. Dyadic is also using their technology in development and manufacturing of Adenol-associated viral vectors (AAV) and certain metabolites.
Dyadic is collaborating with the Israel Institute for Biological Research (IIBR) on a treatment and a vaccine against COVID-19. IIBR are using Dyadic’s C1 gene expression platform to produce vaccine candidates and monoclonal antibodies to potentially prevent or treat COVID-19.
- COVID-19COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the World Health Organization.
- BiotechnologyBiotechnology in a broad sense includes the use of living systems and organisms, as well as their parts for the development or production of products.